The most-read FDA approval stories of 2021 include Tyrvaya nasal spray and Byooviz, the first ophthalmology biosimilar to receive FDA approval.
Read more about the FDA approvals below.
Tyrvaya nasal spray receives FDA approval for treatment of dry eye disease
The FDA approved Tyrvaya nasal spray for the treatment of signs and symptoms of dry eye disease, according to a press release from Oyster Point Pharma. Read more.
FDA approves Byooviz, first ophthalmology biosimilar
The FDA has approved Byooviz as a biosimilar to Lucentis for the treatment of some retinal diseases and conditions, including